采用联合 BRAF 和 MEK 抑制治疗朗格汉斯细胞组织细胞增生症的长期疾病控制。
Long-term disease control of Langerhans cell histiocytosis using combined BRAF and MEK inhibition.
机构信息
Department of Medical Oncology, Universitair Ziekenhuis Brussel, Brussels, Belgium.
Department of Dermatology, Hôpital Erasme, Brussels, Belgium; and.
出版信息
Blood Adv. 2018 Aug 28;2(16):2156-2158. doi: 10.1182/bloodadvances.2018021782.
Abstract
Treatment with a BRAF and MEK inhibitor can achieve a sustained response in -mutant Langerhans cell histiocytosis. Detection of plasma -mutant circulating tumor DNA is a promising biomarker for monitoring disease activity in this entity.
摘要
BRAF 和 MEK 抑制剂治疗可使 - 突变朗格汉斯细胞组织细胞增生症获得持续缓解。检测血浆 - 突变循环肿瘤 DNA 是监测该实体疾病活动的一种很有前途的生物标志物。
相似文献
1
Long-term disease control of Langerhans cell histiocytosis using combined BRAF and MEK inhibition.采用联合 BRAF 和 MEK 抑制治疗朗格汉斯细胞组织细胞增生症的长期疾病控制。
Blood Adv. 2018 Aug 28;2(16):2156-2158. doi: 10.1182/bloodadvances.2018021782.
2
Vemurafenib Use in an Infant for High-Risk Langerhans Cell Histiocytosis.维莫非尼在一名患有高危朗格汉斯细胞组织细胞增多症的婴儿中的应用。
JAMA Oncol. 2015 Sep;1(6):836-8. doi: 10.1001/jamaoncol.2015.0736.
3
Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms.多样且可靶向的激酶改变驱动组织细胞肿瘤。
Cancer Discov. 2016 Feb;6(2):154-65. doi: 10.1158/2159-8290.CD-15-0913. Epub 2015 Nov 13.
4
Langerhans cell histiocytosis: A neoplastic disorder driven by Ras-ERK pathway mutations.朗格汉斯细胞组织细胞增生症：一种由 Ras-ERK 通路突变驱动的肿瘤性疾病。
J Am Acad Dermatol. 2018 Mar;78(3):579-590.e4. doi: 10.1016/j.jaad.2017.09.022. Epub 2017 Oct 26.
5
Langerhans cell histiocytosis associated with classical Hodgkin lymphoma contains BRAF V600E mutation.与经典型霍奇金淋巴瘤相关的朗格汉斯细胞组织细胞增多症含有BRAF V600E突变。
Ann Hematol. 2019 Jan;98(1):231-233. doi: 10.1007/s00277-018-3425-3. Epub 2018 Jul 12.
6
BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy.BRAF突变与高危朗格汉斯细胞组织细胞增多症相关，并与一线治疗耐药性增加有关。
J Clin Oncol. 2016 Sep 1;34(25):3023-30. doi: 10.1200/JCO.2015.65.9508. Epub 2016 Jul 5.
7
Longitudinal assessment of peripheral blood BRAFV600E levels in patients with Langerhans cell histiocytosis.朗格汉斯细胞组织细胞增生症患者外周血 BRAFV600E 水平的纵向评估。
Pediatr Res. 2019 May;85(6):856-864. doi: 10.1038/s41390-018-0238-y. Epub 2018 Nov 24.
8
A circulating subset of BRAF -positive cells in infants with high-risk Langerhans cell histiocytosis treated with BRAF inhibitors.BRAF 抑制剂治疗高危朗格汉斯细胞组织细胞增生症婴儿中 BRAF 阳性细胞的循环亚群。
Br J Haematol. 2021 Aug;194(4):745-749. doi: 10.1111/bjh.17721. Epub 2021 Jul 26.
9
Combination of RAF and MEK inhibition for the treatment of BRAF-mutated melanoma: feedback is not encouraged.联合 RAF 和 MEK 抑制治疗 BRAF 突变型黑色素瘤：不鼓励反馈。
Cancer Cell. 2014 Nov 10;26(5):603-4. doi: 10.1016/j.ccell.2014.10.017.
10
High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis.肢端肥大细胞组织细胞增生症中 BRAF V600E 阴性患者存在高频率的体细胞 MAP2K1 突变。
Blood. 2014 Sep 4;124(10):1655-8. doi: 10.1182/blood-2014-05-577361. Epub 2014 Jun 30.
引用本文的文献
1
Unraveling cutaneous histiocytosis: insights into histology, pathogenesis, diagnosis, and treatment pitfalls.解读皮肤组织细胞增多症：对组织学、发病机制、诊断及治疗陷阱的见解
Front Med (Lausanne). 2025 Jun 20;12:1585815. doi: 10.3389/fmed.2025.1585815. eCollection 2025.
2
Adult Langerhans cell histiocytosis with multi‑system bone, skin, lung and liver involvement: A case report.成人朗格汉斯细胞组织细胞增多症伴多系统骨骼、皮肤、肺和肝脏受累：一例报告。
Biomed Rep. 2024 Sep 2;21(5):162. doi: 10.3892/br.2024.1850. eCollection 2024 Nov.
3
International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults.国际专家共识建议：成人朗格汉斯细胞组织细胞增生症的诊断与治疗。
Blood. 2022 Apr 28;139(17):2601-2621. doi: 10.1182/blood.2021014343.
4
Adult Langerhans Cell Histiocytosis and the Skeleton.成人朗格汉斯细胞组织细胞增生症与骨骼
J Clin Med. 2022 Feb 9;11(4):909. doi: 10.3390/jcm11040909.
5
Vemurafenib provides a rapid and robust clinical response in pediatric Langerhans cell histiocytosis with the BRAF V600E mutation but does not eliminate low-level minimal residual disease per ddPCR using cell-free circulating DNA.维莫非尼在携带 BRAF V600E 突变的儿童朗格汉斯细胞组织细胞增生症中提供了快速而显著的临床应答，但使用游离循环细胞 DNA 的 ddPCR 并不能消除低水平的微小残留病灶。
Int J Hematol. 2021 Dec;114(6):725-734. doi: 10.1007/s12185-021-03205-8. Epub 2021 Aug 12.
6
Update on Pulmonary Langerhans Cell Histiocytosis.肺朗格汉斯细胞组织细胞增多症的最新进展
Front Med (Lausanne). 2021 Mar 8;7:582581. doi: 10.3389/fmed.2020.582581. eCollection 2020.
7
BRAF V600E-Positive Congenital Multisite Langerhans Cell Histiocytosis.BRAF V600E阳性先天性多部位朗格汉斯细胞组织细胞增多症
Cureus. 2020 Sep 2;12(9):e10200. doi: 10.7759/cureus.10200.
8
Efficacy of BRAF-Inhibitor Therapy in BRAF -Mutated Adult Langerhans Cell Histiocytosis.BRAF抑制剂疗法对BRAF突变型成人朗格汉斯细胞组织细胞增多症的疗效
Oncologist. 2020 Dec;25(12):1001-1004. doi: 10.1002/onco.13541. Epub 2020 Oct 12.
9
Effectiveness and Safety of Dabrafenib in the Treatment of 20 Chinese Children with BRAFV600E-Mutated Langerhans Cell Histiocytosis.达巴非尼治疗 20 例 BRAFV600E 突变朗格汉斯细胞组织细胞增生症患儿的有效性和安全性。
Cancer Res Treat. 2021 Jan;53(1):261-269. doi: 10.4143/crt.2020.769. Epub 2020 Sep 15.
10
High-risk LCH in infants is serially transplantable in a xenograft model but responds durably to targeted therapy.婴儿高危朗格汉斯细胞组织细胞增多症在异种移植模型中可连续移植，但对靶向治疗有持久反应。
Blood Adv. 2020 Feb 25;4(4):717-727. doi: 10.1182/bloodadvances.2019032367.
本文引用的文献
1
Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study.维莫非尼治疗 BRAF V600 突变型 Erdheim-Chester 病和朗格汉斯细胞组织细胞增生症：来自组织学独立、开放标签 VE-BASKET 研究的数据分析。
JAMA Oncol. 2018 Mar 1;4(3):384-388. doi: 10.1001/jamaoncol.2017.5029.
2
Circulating cell-free BRAF as a biomarker in children with Langerhans cell histiocytosis.循环无细胞 BRAF 作为朗格汉斯细胞组织细胞增生症患儿的生物标志物。
Br J Haematol. 2017 Aug;178(3):457-467. doi: 10.1111/bjh.14695. Epub 2017 Apr 25.
3
Histiocytoses: emerging neoplasia behind inflammation.组织细胞增多症：炎症背后的新兴肿瘤。
Lancet Oncol. 2017 Feb;18(2):e113-e125. doi: 10.1016/S1470-2045(17)30031-1.
4
Trametinib after disease reactivation under dabrafenib in Erdheim-Chester disease with both and mutations.达拉非尼治疗后 Erdheim-Chester 病再次激活，伴 和 突变，使用曲美替尼治疗。
Blood. 2017 Feb 16;129(7):879-882. doi: 10.1182/blood-2016-09-740217. Epub 2016 Dec 9.
5
Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF/MEK inhibitors.对BRAF V600突变型循环游离肿瘤DNA进行定量评估，作为接受BRAF/MEK抑制剂治疗的转移性黑色素瘤患者治疗监测的工具。
J Transl Med. 2016 Apr 19;14:95. doi: 10.1186/s12967-016-0852-6.
6
Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages.巨噬细胞-树突状细胞谱系组织细胞增多症和肿瘤的修订分类
Blood. 2016 Jun 2;127(22):2672-81. doi: 10.1182/blood-2016-01-690636. Epub 2016 Mar 10.
7
Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.达拉非尼联合曲美替尼治疗 BRAF V600 突变型转移性黑色素瘤患者的总生存和持久应答。
J Clin Oncol. 2016 Mar 10;34(8):871-8. doi: 10.1200/JCO.2015.62.9345. Epub 2016 Jan 25.
8
Improved overall survival in melanoma with combined dabrafenib and trametinib.达拉非尼和曲美替尼联合治疗可改善黑色素瘤患者的总生存期。
N Engl J Med. 2015 Jan 1;372(1):30-9. doi: 10.1056/NEJMoa1412690. Epub 2014 Nov 16.
9
Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders.系统性组织细胞增多症患者游离DNA中BRAFV600E突变检测的前瞻性盲法研究。
Cancer Discov. 2015 Jan;5(1):64-71. doi: 10.1158/2159-8290.CD-14-0742. Epub 2014 Oct 16.
10
The BRAF-V600E mutation in circulating cell-free DNA is a promising biomarker of high-risk adult Langerhans cell histiocytosis.循环游离DNA中的BRAF-V600E突变是高危成年朗格汉斯细胞组织细胞增多症的一个有前景的生物标志物。
Blood. 2014 Oct 16;124(16):2610-1. doi: 10.1182/blood-2014-08-596080.
Zotero 插件